IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.76−0.01 (-1.86%)
Close on Nov 20, 2026Market cap $7.47MP/E –Yield –
IN8bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$3.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.12M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.87M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.57M | – |
See a number that looks wrong?